 ATLANTA, GA, Feb. 06, 2020 GLOBE NEWSWIRE -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. GOVX GOVXD, a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today commented on the recent discontinuance of the HVTN 702 clinical trial. On February 3, 2020, the National Institute of Allergy and Infectious Diseases NIAID, part of the National Institutes of Health NIH, announced that it has stopped administration of vaccinations in its HVTN 702 clinical trial of an investigational HIV vaccine. 